Apyx Medical ( (APYX) ) has released its Q1 earnings. Here is a breakdown of the information Apyx Medical presented to its investors.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Apyx Medical Corporation is an advanced energy technology company specializing in helium plasma and radiofrequency platform technology, primarily serving the cosmetic surgery market with its Renuvion and J-Plasma products. The company is recognized for its innovative approach in providing controlled heat to tissue, enhancing surgical outcomes.
In its first quarter of 2025, Apyx Medical reported a total revenue of $9.4 million, a decrease from the previous year’s $10.2 million. Despite this decline, the Advanced Energy segment showed a 6% increase in revenue, driven by strong sales of generator units and single-use handpieces in the U.S. The company is also preparing for the launch of its AYON Body Contouring System, pending FDA clearance.
Key financial highlights include a significant reduction in net loss attributable to stockholders, which decreased by 45% to $4.2 million. The adjusted EBITDA loss also improved, decreasing by 54% to $2.4 million. The company achieved a gross profit margin of 60%, up from 58% the previous year, due to a favorable product and geographic mix.
Apyx Medical is actively working on expanding its product offerings with the anticipated launch of the AYON Body Contouring System later in 2025. The company remains focused on maintaining its leadership in surgical aesthetics and is optimistic about future growth opportunities, particularly in addressing the needs of patients on GLP-1 drugs.
Looking ahead, Apyx Medical reaffirms its financial guidance for the full year 2025, with expected total revenue between $47.6 million and $49.0 million. The company continues to monitor external factors such as trade policies and tariffs that could impact its operations, while remaining committed to its strategic goals.